Neurostressprofil – Beispiel 1 Ausgangssituation Personalchef, 53

Neurostressprofil – Beispiel 1 Ausgangssituation Personalchef, 53

Neurostressprofil – Beispiel 1
Ausgangssituation
Personalchef, 53 Jahre
Beschwerden: chronischer Stress, Gewichtszunahme, Müdigkeit, Kopfschmerzen
 u

 
 1959


 
 

 
u

185
cm
Gewicht
92
kg
Body Mass Index
26,9
Ausgang 29.10.2007


u
uuu
u
uuu


uuuuuuu
uu
u


uuuu


Speichel Hormone













Erfahrungsbereich für 2. Morgenurin, kein Normbereich








u

u













u























Hormonersatztherapie (HRT): Frauen
Oral
(5-10mg)
80 - 240 pg/ml
Dermal (5mg)
105 - 300 pg/ml


Männer
120 - 335 pg/ml
135 - 400 pg/ml


Neurostressprofil – Beispiel 1
6 Monate später bei angepasster Therapie
Personalchef, 53 Jahre
 u

 
 1959


 
 

 
u

185
cm
Gewicht
92
kg
Body Mass Index
26,9
Ausgang 24.04.2008


uu
uuu

uuuu
uu


uu

uu
uuuu

uuuu
u
uuuuu
uuuu

Speichel Hormone


0,90




36,3



69,6




Erfahrungsbereich für 2. Morgenurin, kein Normbereich


1,3




23,8


u

18,4
u



100,9




158




0,7


u

20,4




8,09




1,70




1,10




10,9




1064,50


Hormonersatztherapie (HRT): Frauen
Oral
(5-10mg)
80 - 240 pg/ml
Dermal (5mg)
105 - 300 pg/ml


949,80
Männer
120 - 335 pg/ml
135 - 400 pg/ml


Neurostressprofil – Beispiel 2
Unternehmerin, 40 Jahre
Beschwerden: Müdigkeit, Konzentrationsschwäche, fehlende Motivation
 uuu

 
1967
 

 
 

 
u

168
cm
Gewicht
60
kg
Body Mass Index
21,3
Ausgang 17.10.2007



u
u

u
u


uuuuu
uu

u
uu
uuuu
uuuuu
uuuuu

uuuuuu

 
Eingang 25.09.2007
 uu
 


Speichel Hormone








Erfahrungsbereich für 2. Morgenurin, kein Normbereich
Prämenopause
Follikelphase
1 - 20 pg/ml


Peak
4 - 30 
Lutealphase
0,5 - 12




Postmenopause
0,5 - 2,7
HRT:
u

u

E2 oral
1,2 - 3,9 pg/ml
E2 dermal
1,2 - 3,9
pg/ml
(gefunden
werden: 2,9 - 35,5)



Biestrogen dermal
1,2 - 3,9 pg/ml
(gefunden werden: 2,4 - 11,6)



Zyklus
Follikelphase
u
Lutealphase
Postmenopause




12 - 120 pg/ml
 75 - 300
 10 - 120










Hormonersatztherapie (HRT):




Kontrazeptivum
10 - 53 pg/ml

 30 - 300 pg/ml


Oral (100 mg)
Dermal (20 mg)
30 - 600 pg/ml (gefunden werden: 200 - 3000)



 Frauen
Hormonersatztherapie (HRT):
Oral
(5-10mg)
jedes Alter
Dermal
(5mg)
16 - 30

31 - 50
51 - 70
ab 70
Seite 1
Frauen
80
- 240 pg/ml
16 - 300
55 pg/ml
105
18 - 55
16 - 47
16 - 47
10 - 38
Hormonersatztherapie (HRT):
topisch
25-50 mg
5-10 mg
0,3-0,5 mg
22 - 86


Männer


Männer
120 - 335 pg/ml
44
- 148
135
400 pg/ml
72 - 148


58 - 1
44 - 94
30 - 77
44 - 148 (gefunden werden:1300 - 3700)
44 - 148 (gefunden werden: 110 - 800)
-
uuuuu
uu

u
Neurostressprofil
– Beispiel 2
uu
uuuu
uuuuu
Fortsetzung
 uuu
 
uuuuu


 
 

uuuuuu
 
 


u



168
cmHormone
Gewicht
Speichel

Prämenopause
60
kg
Body Mass Index

Ausgang 17.10.2007
21,3

Follikelphase
Peak

Lutealphase

1
4
0,5
0,5
-

20 pg/ml
30
12
2,7
Postmenopause
HRT:
u
E2 oral
1,2 - 3,9 pg/ml
E2 dermal
1,2 - 3,9 pg/ml
(gefunden werden: 2,9 - 35,5)
u
Biestrogen dermal
1,2 - 3,9 pg/ml
(gefunden werden: 2,4 - 11,6)



u
u
Zyklus
Follikelphase
12 - 120 pg/ml

Lutealphase
Postmenopause


75 - 300
10 - 120
Hormonersatztherapie (HRT):

Kontrazeptivum
10 - 53 pg/ml
uuuuu
Oral (100 mg)
30 - 300 pg/ml
uu
Dermal (20 mg)
30 - 600 pg/ml (gefunden werden: 200 - 3000)





u
jedes Alter
Frauen
16 - 55
Männer
44 - 148
10 - 38
30 - 77
uu
16 - 30
18 - 55
72 - 148
uuuu
31 - 50
16 - 47
58 - 1
51 - 70
16 - 47
44 - 94
uuuuu
ab 70
uuuuu
Hormonersatztherapie (HRT):

topisch
25-50 mg
44 - 148 (gefunden werden:1300 - 3700)
5-10 mg
-
44 - 148 (gefunden werden: 110 - 800)
0,3-0,5 mg
22 - 86
uuuuuu


Speichel Hormone

Prämenopause


Follikelphase
Peak
Lutealphase
Postmenopause
HRT:
E2 oral
E2 dermal
Biestrogen dermal

1
4
0,5
0,5
-
20 pg/ml
30
12
2,7
1,2 - 3,9 pg/ml
1,2 - 3,9 pg/ml
1,2 - 3,9 pg/ml

Zyklus
Follikelphase
Lutealphase
Postmenopause

(gefunden werden: 2,9 - 35,5)
(gefunden werden: 2,4 - 11,6)


12 - 120 pg/ml
75 - 300
10 - 120
Hormonersatztherapie (HRT):
Kontrazeptivum
10 - 53 pg/ml
Oral (100 mg)
30 - 300 pg/ml
Dermal (20 mg)
30 - 600 pg/ml (gefunden werden: 200 - 3000)

jedes Alter
16 - 30
31 - 50
51 - 70
ab 70


Frauen
16 - 55
18 - 55
16 - 47
16 - 47
10 - 38
Hormonersatztherapie (HRT):
topisch
25-50 mg
5-10 mg
0,3-0,5 mg
22 - 86
Seite 2

Männer
44 - 148
72 - 148
58 - 1
44 - 94
30 - 77
44 - 148 (gefunden werden:1300 - 3700)
44 - 148 (gefunden werden: 110 - 800)
-